Literature DB >> 12713442

Biochemical characterization of the active heterodimer form of human heparanase (Hpa1) protein expressed in insect cells.

Edward McKenzie1, Kathryn Young, Margaret Hircock, James Bennett, Maina Bhaman, Robert Felix, Paul Turner, Alasdair Stamps, David McMillan, Giles Saville, Stanley Ng, Sean Mason, Daniel Snell, Darren Schofield, Haiping Gong, Reid Townsend, John Gallagher, Martin Page, Raj Parekh, Colin Stubberfield.   

Abstract

The mammalian endoglycosidase heparanase (Hpa1) is primarily responsible for cleaving heparan sulphate proteoglycans (HSPGs) present on the basement membrane of cells and its potential for remodelling the extracellular matrix (ECM) could be important in embryonic development and tumour metastasis. Elevated expression of this enzyme has been implicated in various pathological processes including tumour cell proliferation, metastasis, inflammation and angiogenesis. The enzyme therefore represents a potential therapeutic target. Hpa1 protein is initially synthesized as an inactive 65 kDa proenzyme that is then believed to be subsequently activated by proteolytic cleavage to generate an active heterodimer of 8 and 50 kDa polypeptides. By analysis of a series of Hpa1 deletion proteins we confirm that the 8 kDa subunit is essential for enzyme activity. We present here for the first time an insect cell expression system used for the generation of large amounts of recombinant protein of high specific activity. Individual subunits were cloned into baculoviral secretory vectors and co-expressed in insect cells. Active secreted heterodimer protein was recovered from the medium and isolated by a one-step heparin-Sepharose chromatography procedure to give protein of >90% purity. The recombinant enzyme behaved similarly to the native protein with respect to the size of HS fragments liberated on digestion, substrate cleavage specificity and its preference for acidic pH. A significant amount of activity, however, was also detectable at physiological pH values, as measured both by an in vitro assay and by in vivo degradation of cell-bound heparan sulphate.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12713442      PMCID: PMC1223510          DOI: 10.1042/BJ20030318

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  50 in total

Review 1.  Functions of cell surface heparan sulfate proteoglycans.

Authors:  M Bernfield; M Götte; P W Park; O Reizes; M L Fitzgerald; J Lincecum; M Zako
Journal:  Annu Rev Biochem       Date:  1999       Impact factor: 23.643

2.  Human heparanase: a molecular determinant of brain metastasis.

Authors:  D Marchetti; G L Nicolson
Journal:  Adv Enzyme Regul       Date:  2001

3.  Expression pattern and secretion of human and chicken heparanase are determined by their signal peptide sequence.

Authors:  O Goldshmidt; E Zcharia; H Aingorn; Z Guatta-Rangini; R Atzmon; I Michal; I Pecker; E Mitrani; I Vlodavsky
Journal:  J Biol Chem       Date:  2001-05-31       Impact factor: 5.157

4.  Expression of heparanase in normal, dysplastic, and neoplastic human colonic mucosa and stroma. Evidence for its role in colonic tumorigenesis.

Authors:  Y Friedmann; I Vlodavsky; H Aingorn; A Aviv; T Peretz; I Pecker; O Pappo
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

5.  Expression of heparanase in oral cancer cell lines and oral cancer tissues.

Authors:  M Ikuta; K A Podyma; K Maruyama; S Enomoto; M Yanagishita
Journal:  Oral Oncol       Date:  2001-02       Impact factor: 5.337

6.  Heparanase expression in primary and metastatic pancreatic cancer.

Authors:  A Koliopanos; H Friess; J Kleeff; X Shi; Q Liao; I Pecker; I Vlodavsky; A Zimmermann; M W Büchler
Journal:  Cancer Res       Date:  2001-06-15       Impact factor: 12.701

7.  Heparanase protein and gene expression in bladder cancer.

Authors:  K Gohji; M Okamoto; S Kitazawa; M Toyoshima; J Dong; Y Katsuoka; M Nakajima
Journal:  J Urol       Date:  2001-10       Impact factor: 7.450

8.  Identification of active-site residues of the pro-metastatic endoglycosidase heparanase.

Authors:  M D Hulett; J R Hornby; S J Ohms; J Zuegg; C Freeman; J E Gready; C R Parish
Journal:  Biochemistry       Date:  2000-12-26       Impact factor: 3.162

9.  Heparanase expression in invasive trophoblasts and acute vascular damage.

Authors:  L A Dempsey; T B Plummer; S L Coombes; J L Platt
Journal:  Glycobiology       Date:  2000-05       Impact factor: 4.313

Review 10.  Modulation of leukocyte behavior by an inflamed extracellular matrix.

Authors:  H Schor; G G Vaday; O Lider
Journal:  Dev Immunol       Date:  2000
View more
  34 in total

1.  Significance of heparanase in cancer and inflammation.

Authors:  Israel Vlodavsky; Phillip Beckhove; Immanuel Lerner; Claudio Pisano; Amichai Meirovitz; Neta Ilan; Michael Elkin
Journal:  Cancer Microenviron       Date:  2011-08-03

2.  Adaptive evolution of heparanase in hypoxia-tolerant Spalax: gene cloning and identification of a unique splice variant.

Authors:  Nicola J Nasser; Eviatar Nevo; Itay Shafat; Neta Ilan; Israel Vlodavsky; Aaron Avivi
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-04       Impact factor: 11.205

3.  Heparanase localization and expression by head and neck cancer: correlation with tumor progression and patient survival.

Authors:  Ilana Doweck; Victoria Kaplan-Cohen; Inna Naroditsky; Edmond Sabo; Neta Ilan; Israel Vlodavsky
Journal:  Neoplasia       Date:  2006-12       Impact factor: 5.715

4.  Antisense-mediated suppression of Heparanase gene inhibits melanoma cell invasion.

Authors:  Madhuchhanda Roy; Jane Reiland; Brian P Murry; Vladimir Chouljenko; Konstantin G Kousoulas; Dario Marchetti
Journal:  Neoplasia       Date:  2005-03       Impact factor: 5.715

Review 5.  Versatile role of heparanase in inflammation.

Authors:  Rachel Goldberg; Amichay Meirovitz; Nir Hirshoren; Raanan Bulvik; Adi Binder; Ariel M Rubinstein; Michael Elkin
Journal:  Matrix Biol       Date:  2013-03-13       Impact factor: 11.583

Review 6.  Involvement of heparanase in atherosclerosis and other vessel wall pathologies.

Authors:  Israel Vlodavsky; Miry Blich; Jin-Ping Li; Ralph D Sanderson; Neta Ilan
Journal:  Matrix Biol       Date:  2013-03-13       Impact factor: 11.583

7.  Cathepsin L is responsible for processing and activation of proheparanase through multiple cleavages of a linker segment.

Authors:  Ghada Abboud-Jarrous; Ruth Atzmon; Tamar Peretz; Carmela Palermo; Bedrick B Gadea; Johanna A Joyce; Israel Vlodavsky
Journal:  J Biol Chem       Date:  2008-04-30       Impact factor: 5.157

8.  HIP/RPL29 antagonizes VEGF and FGF2 stimulated angiogenesis by interfering with HS-dependent responses.

Authors:  Sonia D'Souza; Weidong Yang; Dario Marchetti; Caroline Muir; Mary C Farach-Carson; Daniel D Carson
Journal:  J Cell Biochem       Date:  2008-12-01       Impact factor: 4.429

9.  Heparanase promotes engraftment and prevents graft versus host disease in stem cell transplantation.

Authors:  Menachem Bitan; Lola Weiss; Michael Zeira; Eyal Zcharia; Shimon Slavin; Arnon Nagler; Israel Vlodavsky
Journal:  PLoS One       Date:  2010-04-15       Impact factor: 3.240

10.  The PG500 series: novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy.

Authors:  K Dredge; E Hammond; K Davis; C P Li; L Liu; K Johnstone; P Handley; N Wimmer; T J Gonda; A Gautam; V Ferro; I Bytheway
Journal:  Invest New Drugs       Date:  2009-04-09       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.